Marketing and manufacturing practices for compounded GLP-1RA drugs have come under FDA scrutiny, prompting policy changes.

Researchers say GLP-1 drugs prescribed for weight loss like Ozempic and Mounjaro are more effective at reducing heart health ...

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs. An alarming 40% of orders for glucagon-like peptide-1 ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered significant attention recently, both in the media and in ...

PATIENTS with systemic lupus erythematosus (SLE) and Type 2 diabetes (T2D) had significantly lower cardiovascular, kidney, ...

In this cohort study, 40% of orders for glucagon-like peptide-1 receptor agonists (GLP-1RAs) were not filled. Non-Hispanic Black patients and Hispanic patients were less likely to fill orders than non ...

USA: A new study published in Arthritis & Rheumatology found that patients with lupus and type 2 diabetes, including those ...

Discover how FTIR spectroscopy enhances quality control in GLP-1 weight loss drug production by ensuring molecular ...

Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another ...

Though nimacimab failed to trigger weight loss as a monotherapy, analysts are intrigued by the drug’s activity alongside ...

The use of GLP-1RAs may improve RA disease activity and cardiovascular risk profiles among patients with overweight or obesity.